Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;25(1):135-8.
doi: 10.1038/cr.2014.141. Epub 2014 Nov 4.

EGF promotes mammalian cell growth by suppressing cellular senescence

Affiliations

EGF promotes mammalian cell growth by suppressing cellular senescence

Peter B Alexander et al. Cell Res. 2015 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anti-senescence function of EGF in human epithelial cells and mouse tissues. (A-C) EGF depletion results in cellular senescence of HME cells. HME cells were exposed for 1 week to complete culture medium or to medium lacking EGF. Cells cultured in the absence of EGF displayed an enlarged morphology, elevated SA-β-gal activity (A), decreased proliferation (B), and reduced Rb phosphorylation and elevated p21 expression (C), all markers that are commonly associated with cellular senescence. (D-H) EGFR pharmacological inhibition causes cellular senescence of HME cells. In D and E, HME cells were treated for three days with complete culture medium supplemented with increasing concentrations of erlotinib. Cells were then stained for SA-β-gal activity (D), or metabolically labeled with 2 μCi of [3H]-thymidine for 16 h (E). Progressively decreasing amounts of label incorporation were observed for cells cultured in the presence of erlotinib. Experiments were performed in triplicate; error bars indicate SD. In F-H, quantification of erlotinib-induced cellular senescence of HME cells using flow cytometry. HME cells were exposed to 1 μM erlotinib for 24 or 48 h and then analyzed for SA-β-gal activity using either a chromogenic assay (F) or a fluorescence-based assay (G and H, see Supplementary information, Data S1). Both assay types indicated that SA-β-gal reached maximal activity from 24 to 48 h after treatment. (A, D, F) Scale bar, 50 μm. (I-M) Mice treated with erlotinib display early aging-associated phenotypes. Skin atrophy in erlotinib-treated mice. BALB/c nude mice (five per group) were treated with either vehicle or erlotinib (50 mg/kg/day) for 4 weeks. Skin was fixed in 4% PFA, stained using H&E, and photographed at 10× magnification. Note the reduced epidermal thickness and fat content resulting from EGFR inhibition. E, epidermis; D, dermis; F, fat; M, muscle. Scale bar, 250 μm. (I). Reduced weight of mice treated with daily erlotinib. Error bars indicate SD (J). Representative photograph and X-ray of tumor-bearing BALB/c nude mice treated with vehicle or erlotinib. Note the reduced size, kyphosis, and generally aged appearance of the erlotinib-treated mouse (K). Spleen atrophy in erlotinib-treated mice (see also Supplementary information, Figure S1P-S1Q) (L). Immunohistochemical staining of skin and spleen tissue from vehicle- or erlotinib-treated mice was performed using an antibody specific for p16. Images shown were photographed at 40×. Scale bar, 100 μm (M).

Similar articles

Cited by

References

    1. 1Kuilman T, Michaloglou C, Mooi WJ, et al. Genes Dev 2010; 24:2463–2479. - PMC - PubMed
    1. 2Tropepe V, Sibilia M, Ciruna BG, et al. Dev Biol 1999; 208:166–188. - PubMed
    1. 3Debacq-Chainiaux F, Erusalimsky JD, Campisi J, et al. Nat Protoc 2009; 4:1798–1806. - PubMed
    1. 4Coppe JP, Patil CK, Rodier F, et al. PLoS Biol 2008; 6:2853–2868. - PMC - PubMed
    1. 5Roberts RB, Arteaga CL, Threadgill DW. Cancer Cell 2004; 5:115–120. - PubMed

Publication types

LinkOut - more resources